Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2013

View Archived Issues

HDAC9 gene polymorphism associated with large vessel disease stroke subtype

Cardiac and renal benefits of M-ANP in a preclinical model of heart failure

RP-6503 shows efficacy in cellular and animal models of airway disorders

Urinary microRNAs identified as biomarkers of focal segmental glomerulosclerosis

FDA accepts IND for Edge Therapeutics' EG-1962

ePharmaSolutions to provide AstraZeneca Neuroscience with clinical trial portal

FF-21101 shows promising results in vivo

Vitaros approved in Europe for erectile dysfunction

Trevena presents new mu opioid receptor-biased ligand

FDA grants orphan drug status to TH-302, SL-401 and Pheburane

OncoSec Medical collaborates with Old Dominion University for melanoma study

Abbott begins ABSORB trial in Japan

UCB to collaborate with Crelux and 4SC Discovery in neurology

Chinese group discloses novel PI3Kalpha and mTOR inhibitors

Redx Pharma presents new antibacterial agents

Ariad Pharmaceuticals begins phase II trial of ponatinib in GIST

New HCV NS3 protease inhibitors synthesized

Boehringer Ingelheim to build biopharmaceuticals facility in China

Deciphera Pharmaceuticals patents novel c-Met inhibitors

New international collaboration to develop GPBA receptor agonists for type 2 diabetes

Daiichi Sankyo launches Pralia in Japan

Roche divulges new cathepsin inhibitors

SanBio receives IND clearance for phase I/IIa study of SB-623 for traumatic brain injury

Updated findings from phase II study of 90Y-epratuzumab following R-CHOP in DLBCL

Biota initiates phase II trial of laninamivir octanoate for treatment of influenza

Cerus initiates patient enrollment in two phase III clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...